US task force under fire for recommending against glaucoma screening

Article

A conference, which was set up in response to the recent report by the US Preventive Services Task Force (USPSTF) dismissing the importance of glaucoma screening, has recommended a re-evaluation of the findings.

A conference, which was set up in response to the recent report by the US Preventive Services Task Force (USPSTF) dismissing the importance of glaucoma screening, has recommended a re-evaluation of the findings.

The task force assigned to the USPSTF investigation conducted a review of the clinical trials literature but failed to find conclusive proof supporting the screening of glaucoma, thereby determining that there is insufficient scientific evidence to recommend for or against glaucoma screening in Americans. However, since the report was published, the USPSTF has so far declined to respond to public comment presenting new information.

Participants at the conference, which ranged from glaucoma patients and scientific experts to the former Commissioner of the FDA and the former Surgeon General of the US Navy, discussed the urgent need for a review of the evidence, highlighting the potential future harm to 2 million glaucoma patients at risk of blindness if the report is incorporated into national policy.

Scientists at the conference presented new data which established a link between early glaucomatous optic nerve loss and loss of visual function. Data files maintained by Medicare also demonstrated that moderate vision loss can incur an additional cost on the federal budget.

Representatives from organizations including Medicare and the Veterans Administration agreed that the USPSTF findings were inconsistent with independent scientific reviews undertaken by their own organizations. The group also stressed the need for a clearer and more open process on how to interpret and develop upon medical evidence.

The Potomac Institute for Policy Studies, who co-hosted the conference along with the Glaucoma Foundation, is releasing a report outlining its policy recommendations before the end of this year.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.